Target MAP in Septic Shock with Chronic Hypertension
Primary MAP Target
In adult patients with septic shock and chronic hypertension, target a mean arterial pressure (MAP) of 70–85 mmHg rather than the standard 65 mmHg to reduce acute kidney injury, accepting a higher risk of arrhythmias. 1, 2
For patients without chronic hypertension, maintain MAP ≥ 65 mmHg as the initial target. 1, 2
Evidence Supporting Higher Targets in Chronic Hypertension
The SEPSISPAM trial demonstrated that targeting MAP 80–85 mmHg versus 65–70 mmHg in patients with chronic hypertension significantly reduced the need for renal replacement therapy, though overall mortality was unchanged. 1, 3, 4
Patients with chronic hypertension have a rightward shift in their autoregulatory curve, meaning their organs require higher perfusion pressures to maintain adequate blood flow. 1, 5
The higher MAP target (70–85 mmHg) in hypertensive patients comes with an increased risk of atrial fibrillation and other arrhythmias due to higher vasopressor doses required. 1, 3
Maximum Safe MAP
There is no absolute "maximum" MAP, but targeting MAP > 85 mmHg provides no additional benefit and substantially increases the risk of arrhythmias and excessive vasopressor-related complications. 1, 3
MAP targets above 85 mmHg do not improve mortality, organ function, or tissue perfusion markers. 3, 4
Excessive vasopressor doses needed to achieve very high MAP targets (>85 mmHg) cause end-organ ischemia, particularly cardiac, digital, and splanchnic ischemia. 2
Practical Implementation Algorithm
Step 1: Initial Resuscitation
- Administer at least 30 mL/kg IV crystalloid within the first 3 hours. 1
- Start norepinephrine at 0.05–0.1 µg/kg/min when MAP remains < 65 mmHg after initial fluid bolus. 1, 2
Step 2: Determine Target MAP Based on History
- If chronic hypertension present: Target MAP 70–85 mmHg (consider starting at 70–75 mmHg and titrating up if needed). 1, 5, 3, 4
- If no chronic hypertension: Target MAP ≥ 65 mmHg. 1, 2
Step 3: Vasopressor Escalation
- Titrate norepinephrine to achieve target MAP. 1, 2
- Add vasopressin 0.03 U/min (fixed dose) when norepinephrine reaches 0.1–0.2 µg/kg/min and MAP remains below target. 1, 2
- Add epinephrine 0.05–2 µg/kg/min if MAP target not achieved with norepinephrine plus vasopressin. 1, 2
Step 4: Monitor Beyond MAP
Critical Pitfalls to Avoid
Do not assume MAP 65 mmHg is adequate for all patients—chronic hypertensives require higher targets to prevent renal injury. 1, 5, 3, 4
Do not chase MAP > 85 mmHg—this increases arrhythmia risk without improving outcomes. 3, 4
Do not rely solely on MAP as a perfusion endpoint—normal MAP can coexist with severe tissue hypoperfusion, especially when capillary refill remains prolonged or lactate elevated. 1, 5, 6
Do not exceed vasopressin 0.03–0.04 U/min—higher doses cause cardiac, digital, and splanchnic ischemia without hemodynamic benefit. 2
Do not use dopamine as first-line therapy—it increases mortality by 11% absolute risk and causes more arrhythmias than norepinephrine. 2
Special Considerations
In patients with elevated intra-abdominal pressure, the effective organ perfusion pressure is MAP minus intra-abdominal pressure; you may need higher MAP targets to maintain adequate abdominal perfusion pressure > 60 mmHg. 5
Patients with chronic hypertension who achieve goal MAP more rapidly paradoxically have higher 28-day mortality, suggesting that the underlying severity of illness—not the MAP target itself—drives outcomes. 7
After the early resuscitation phase, microcirculatory dysfunction may persist despite achieving macrocirculatory MAP targets, requiring attention to tissue perfusion markers rather than further MAP escalation. 3